What is the recommended treatment for mild persistent asthma?

The recommended treatment for mild persistent asthma is the use of a low-dose daily inhaled corticosteroid (ICS). Inhaled corticosteroids are considered the first-line therapy for asthma management because they effectively reduce inflammation in the airways, which is a primary underlying issue in asthma. By lowering inflammation, they help to prevent asthmatic symptoms such as wheezing, shortness of breath, and nighttime awakenings.

Mild persistent asthma is characterized by symptoms that occur more than twice a week but not daily, and it may include some nighttime symptoms. The goal of treatment for this level of asthma is to maintain control and prevent exacerbations while using the least amount of medication necessary. A low-dose ICS is sufficient for this purpose and is pivotal in maintaining long-term control.

Other treatment options like using short-acting beta agonists alone are generally discouraged for persistent asthma because they only relieve symptoms without addressing underlying inflammation. Long-acting beta agonists may be appropriate but should be used in combination with ICS for persistent asthma management, not on their own. Oral corticosteroids, while potent anti-inflammatory agents, are typically reserved for more severe asthma due to their side effects and are not considered first-line for mild persistent asthma.